Showing 20 of 67 recruiting trials for “Neuroblastoma”
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
👨⚕️ Holly Meany, MD, Children's National Research Institute📍 2 sites📅 Started Jan 2026View details ↗
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
👨⚕️ Sara Federico, MD, St. Jude Children's Research Hospital📍 1 site📅 Started Nov 2025View details ↗
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
👨⚕️ Jacquelyn Crane, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Jun 2025View details ↗
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
👨⚕️ Jacquelyn Crane, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Mar 2025View details ↗
RecruitingNCT06852807 ↗
18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
RecruitingNCT07141862 ↗
Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method
👨⚕️ Florence BRUGNON, MD, PhD, HDR, University Hospital, Clermont-Ferrand📍 1 site📅 Started Feb 2025View details ↗
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
👨⚕️ Holger Lode, MD, PhD, Princess Maxima Center for Pediatric Oncology📍 1 site📅 Started Jan 2025View details ↗
RecruitingNCT06674811 ↗
Biomarkers of Resiliency In Childhood Cancer Surgery
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Page 1 of 4Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →